

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## **Vital Innovations Holdings Limited**

**維太創科控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6133)**

### **UPDATE ON PUBLICATION OF 2023 ANNUAL RESULTS AND DATE OF BOARD MEETING**

Reference is made to the announcements of Vital Innovations Holdings Limited (the “**Company**”) (i) dated 13 March 2024 in relation to a meeting (the “**Board Meeting**”) of the board (the “**Board**”) of directors of the Company to be held on 26 March 2024 for the purpose of, inter alia, considering and approving the annual results of the Company and its subsidiaries for the year ended 31 December 2023 (“**2023 Annual Results**”) and its publication and considering the payment of a final dividend, if any; and (ii) dated 26 March 2024 in respect of, among other things, the delay in publication of the 2023 Annual Results and the postponement of the Board Meeting.

The Board hereby announces that the Board Meeting has been scheduled to be held on Tuesday, 30 April 2024 for the purpose of, inter alia, considering and approving the 2023 Annual Results and its publication, and considering the payment of a final dividend, if any.

By order of the Board  
**Vital Innovations Holdings Limited**  
**Rong Xiuli**  
*Chairperson*

Hong Kong, 18 April 2024

*As at the date of this announcement, the Board of the Company comprises Ms. Rong Xiuli, Mr. Rong Shengli, Mr. Yin Xuquan and Mr. Wong Ho Chun as executive Directors; and Mr. Han Xiaojing, Mr. Wong Pong Chun James and Mr. Leung Man Fai as independent non-executive Directors.*